VivoSeq
Infectious Disease

Respiratory Syncytial Virus (RSV) Infection

0

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Respiratory Syncytial Virus (RSV) Infection is an early-stage landscape with 0 programs across 7 companies. The most active players are Gilead, Johnson & Johnson, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

62/100

Attrition Rate

36/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalA

Ablynx, a Sanofi company

0 programs

PreclinicalA

Arrow Therapeutics

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed8 · 57%
Terminated4 · 29%
No longer available1 · 7%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

14 trials

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Completed·Gilead logoGilead·Phase 2·NCT02135614·189 enrolled
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Completed·Gilead logoGilead·Phase 2·NCT02534350·61 enrolled
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
Completed·AArrow Therapeutics·Phase 2·NCT00232635·27 enrolled
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
Completed·AbbVie logoAbbVie·Phase 3·NCT02968173·50 enrolled
A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection
Completed·Pfizer logoPfizer·Phase 2·NCT03258502·66 enrolled
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Completed·AAbbott·N/A·NCT01107535·82 enrolled
Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life
Completed·Sanofi logoSanofi·Phase 3·NCT05437510·8,057 enrolled
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Completed·Gilead logoGilead·Phase 2·NCT02254421·60 enrolled
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Terminated·Gilead logoGilead·Phase 2·NCT06784973·4 enrolled
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT02593851·45 enrolled
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT04978337·5 enrolled
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
Terminated·Pfizer logoPfizer·Phase 2/3·NCT06079320·16 enrolled
Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection
Withdrawn·AAblynx, a Sanofi company·Phase 2·NCT03468829
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
No longer available·Johnson & Johnson logoJohnson & Johnson·N/A·NCT04221412

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)